Ieq Capital LLC Has $52.69 Million Holdings in Illumina, Inc. $ILMN

Ieq Capital LLC raised its holdings in Illumina, Inc. (NASDAQ:ILMN) by 27.1% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 401,714 shares of the life sciences company’s stock after acquiring an additional 85,698 shares during the quarter. Ieq Capital LLC’s holdings in Illumina were worth $52,689,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in ILMN. Capital World Investors lifted its stake in Illumina by 20.0% in the third quarter. Capital World Investors now owns 19,976,850 shares of the life sciences company’s stock valued at $1,897,178,000 after buying an additional 3,331,542 shares during the period. Nordea Investment Management AB lifted its stake in Illumina by 2,792.2% in the fourth quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after buying an additional 911,843 shares during the period. Massachusetts Financial Services Co. MA acquired a new position in Illumina in the fourth quarter valued at approximately $73,532,000. Norges Bank acquired a new position in Illumina in the fourth quarter valued at approximately $70,844,000. Finally, State Street Corp lifted its stake in Illumina by 6.8% in the third quarter. State Street Corp now owns 5,999,790 shares of the life sciences company’s stock valued at $569,800,000 after buying an additional 382,520 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $160.97 on Friday. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. Illumina, Inc. has a twelve month low of $85.77 and a twelve month high of $177.22. The stock’s 50 day moving average is $141.65 and its 200-day moving average is $134.99. The firm has a market capitalization of $24.35 billion, a price-to-earnings ratio of 29.27, a PEG ratio of 3.11 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.Illumina’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Sell-side analysts forecast that Illumina, Inc. will post 5.21 EPS for the current fiscal year.

Insider Buying and Selling

In related news, SVP Patricia Leckman sold 783 shares of the company’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This represents a 3.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 235,000 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the completion of the sale, the director owned 2,830,452 shares in the company, valued at $463,146,860.76. This represents a 7.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 1,003,154 shares of company stock worth $155,600,208 over the last ninety days. Insiders own 2.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the company. Royal Bank Of Canada assumed coverage on Illumina in a research note on Thursday, May 14th. They issued an “outperform” rating and a $170.00 price target on the stock. Guggenheim boosted their price target on Illumina from $170.00 to $180.00 and gave the company a “buy” rating in a research note on Monday, June 1st. Citigroup boosted their price target on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research note on Monday, May 4th. Weiss Ratings raised Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. Finally, Barclays boosted their price target on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research note on Friday, May 1st. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $142.13.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.